Cardiovascular effects of dietary salts and isosorbide-5-mononitrate in spontaneously hypertensive rats

Blood Pressure

Volumn 7, Issue 3, 1998, Pages 184-192

  Vaskonen, Timo ^a   Mervaala, Eero ^a   Teräväinen, Terttu Liisa ^a   Laakso, Juha ^b   Karppanen, Heikki ^a   Vapaatalo, Heikki ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b MILA Ltd   (Finland)

Author keywords

Blood pressure; Isosorbide 5 mononitrate; Left ventricular hypertrophy; Magnesium; Potassium; Renal hypertrophy; SHR; Sodium

Indexed keywords

ISOSORBIDE 5 NITRATE; MAGNESIUM ION; POTASSIUM ION; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE; CALCIUM EXCRETION; CARDIOVASCULAR RESPONSE; DOSE RESPONSE; DRUG EFFECT; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HYPERTENSION; KIDNEY HYPERTROPHY; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; SALT INTAKE; URINARY EXCRETION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CATIONS; CONDIMENTS; DELAYED-ACTION PREPARATIONS; HEART RATE; HYPERTENSION; HYPERTROPHY; HYPERTROPHY, LEFT VENTRICULAR; ISOSORBIDE DINITRATE; KIDNEY; MALE; MESENTERIC ARTERIES; RATS; RATS, INBRED SHR; SALTS; SODIUM, DIETARY; VASODILATOR AGENTS;

EID: 0031656991     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/080370598437402     Document Type: Article

References (55)

1. Vapaatalo H. NO-donors in cardiology. Pol J Pharmacol 1994; 46: 531-40.
2. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 1991; 43: 109-42.
3. Lahera V, Salom MG, Fiksen-Olsen MJ, Raij L, Romero JC. Effects of NG-monomethyl-L-arginine and L-arginine on acetylcholine renal response. Hypertension 1990; 15: 659-63.
4. Lahera V, Salom MG, Fiksen-Olsen MJ, Romero JC. Mediatory role of endothelium-derived nitric oxide in renal vasodilatory and excretory effects of bradykinin. Am J Hypertens 1991; 4: 260-2.
5. Rees DD, Palmer RMJ, Schulz R, et al. Characterization of three inhibitors of endothelial nitric oxide synthesis in vitro and in vivo. Br J Pharmacol 1990; 101: 746-52.
6. Schleiffer R, Pernot F, Overloop BV, Gaidard A. In vivo involvement of endothelium-derived nitric oxide in spontaneously hypertensive rats: effects of NG-nitro-L-arginine methyl ester. J Hypertens 1991; 9 (Suppl 6): S192-3.
7. Arnal J-F, Battle T, Menard J, Michel J-B. The vasodilatory effect of endogenous nitric oxide is a major counter-regulatory mechanism in the spontaneously hypertensive rat. J Hypertens 1993; 11: 945-50.
8. Morton JJ, Beattie EC, Speirs A, Gulliver F. Persistent hypertension following inhibition of nitric oxide formation in the young Wistar rat: role of renin and vascular hypertrophy. J Hypertens 1993; 11: 1083-8.
9. Navarro J, Sanchez A, Saiz J, et al. Hormonal, renal and metabolic alterations during hypertension induced by chronic inhibition of NO in rats. Am J Physiol 1994; 267: R1516-21.
10. Rees DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86: 3375-8.
11. Salazar FJ, Alberola A, Pinilla JM, et al. Salt induced increase in arterial pressure during nitric oxide synthesis inhibition. Hypertension 1993; 22: 49-55.
12. Vallance P, Collier J, Moncada S. Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 1989; 2: 997-1000.
13. Vaskonen T, Mervaala E, Krogerus L, et al. Cardiovascular effects of dietary salt and chronic inhibition of nitric oxide synthesis in spontaneously hypertensive rats. Hypertens Res 1997; 20: 183-92.
14. Albino-Teixeira A, Soares-da-Silva P. Isosorbide-5-mononitrate reverses high blood pressure in NG-nitro-L-arginine methyl ester treated rats. Gen Pharmacol 1994; 7: 1329-36.
15. Mervaala EMA, Himberg J-J, Laakso J, Tuomainen P, Karppanen H Beneficial effects of a potassium- and magnesium-enriched salt alternative. Hypertension 1992; 19: 535-40.
16. Mervaala EMA, Laakso J, Karppanen H. Cardiovascular effects of felodipine are not antagonized by dietary salt. Eur J Pharmacol 1994: 255: 73-9.
17. Mervaala EMA, Laakso J, Vapaatalo H, Karppanen H. Improvement of cardiovascular effects of metoprolol by replacement of common salt with a potassium- and magnesium-enriched salt alternative. Br J Pharmacol 1994; 112: 640-8.
18. Mervaala EMA, Laakso JT, Himberg JJ, Karppanen HO. Replacement of regular salt by a novel salt alternative improves the cardiovascular effects of the ACE inhibitor enalapril. Hypertens Res 1994; 17: 59-69.
19. Mervaala EMA, Paakkari I, Laakso J, et al. Replacement of salt by a novel potassium- and magnesium-enriched salt alternative improves the cardiovascular effects of ramipril. Br J Pharmacol 1994; 111: 1189-97.
20. Vaskonen T, Laakso J, Mervaala E, Sievi E, Karppanen H. Interrelationships between salt and fish oil in stroke prone spontaneously hypertensive rats. Blood Pressure 1996; 5: 178-89.
21. Frost CD, Law MR, Wald NJ. By how much does dietary salt reduction lower blood pressure? II. Analysis of observational data within populations. Br Med J 1991; 302: 815-8.
22. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? I. Analysis of observational data among populations. Br Med J 1991; 302: 811-5.
23. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III. Analysis of data from trials of salt reduction. Br Med J 1991; 302: 819-24.
24. Dyer AR, Shipley M, Elliot P. Urinary electrolyte excretion in 24 hours and blood pressure in the INTERSALT study. I. Estimate of reliability. II. Estimate of electrolyte-blood pressure associations corrected for regression dilution bias. Am J Epidemiol 1994; 139: 927-51.
25. McGormick CP, Rauch AL, Buckalew WM Jr. Differential effect of dietary salt on renal growth in Dahl salt-sensitive and salt-resistant rats. Hypertension 1989; 13: 122-7.
26. Mervaala EMA, Laakso J, Vapaatalo H, Karppanen H. Effects of enalapril and hydrochlorothiazide on salt-induced cardiac and renal hypertrophy in normotensive rats. Naunyn Schmiedebergs Arch Pharmacol 1994; 350: 416-25.
27. Shultz PJ, Tolins JP. Adaptation to increased dietary salt intake in the rat: role of endogenous nitric oxide. J Clin Invest 1993; 91: 642-50.
28. Tolins JP, Shultz PJ. Endogenous nitric oxide synthesis determines sensitivity to the pressor effect of salt. Kidney Int 1994; 46: 230-6.
29. Ruilope LM, Lahera V, Rodicio JL, Romero JC. Participation of nitric oxide in the regulation of renal function: possible role in the genesis of arterial hypertension. J Hypertens 1994; 12: 625-31.
30. Whelton PK, He J, Cutler JA, et al. Effects of oral potassium on blood pressure. Meta-analysis of randomized controlled clinical trials. JAMA 1997; 277: 1624-32.
31. Altura BM, Altura BT. Role of magnesium in the pathogenesis of hypertension: relationship to its actions on cardiac and vascular smooth muscle. In: Laragh JH, Brenner BM, eds. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press, 1990: 1003-25.
32. Karppanen H. Epidemiologic evidence for considering magnesium deficiency as a risk factor for cardiovascular diseases. Magnesium Bull 1990; 12: 80-6.
33. Pörsti I, Arvola P, Vuorela H, et al. Effects of a high calcium diet and deoxycorticosterone on vascular smooth muscle responses in spontaneously hypertensive rats. J Hypertens 1991; 8: 835-41.
34. Kähönen M, Arvola P, Vapaatalo H, Pörsti I. Comparison of cumulative and non-cumulative administration of vasoactive agents in arterial smooth muscle responses in vitro. Pharmacol Toxicol 1993; 73: 142-5.
35. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265-75.
36. Axelsson KL, Bornefeldt KE, Norlander B, Wikberg JES. Attomole sensitive radioimmunoassay for cyclic GMP. Second Messengers Phosphoprot 1988; 12: 145-54.
37. Tobian L. Potassium and sodium in hypertension: the Volhard Lecture. J Hypertens 1988; 6 (Suppl 4): 12-24.
38. Oparil S, Meng OC, Chen YF, Yang RH, Jin H, Wyss JM. Genetic basis of NaCl-sensitive hypertension. J Cardiovasc Pharmacol 1988; 12: S56-69.
39. Karppanen H. New oral salt in treatment of high blood pressure. Magnesium 1989; 8: 274-87.
40. Karppanen H, Tanskanen A, Tuomilehto J, et al. Safety and effects of potassium- and magnesium-containing low sodium salt mixtures. J Cardiovasc Pharmacol 1984; 6: 236-43.
41. Gefeijnse J, Witteman J, Bak A, den Breeijen J, Grobbee D. Reduction in Wood pressure with low sodium, high potassium, high magnesium salt in older subjects with mild to moderate hypertension. Br Med J 1994; 309: 436-40.
42. Neutel J. Replacing regular salt with sodium-reduced, potassium- and magnesium-enriched mineral salt may offer a non-pharmacological approach to lowering blood pressure. Am J Hypertens 1996; 9: 94A.
43. Whelton P, Cohen J, Jones D, Weinberger M. The use of a reduced sodium salt containing potassium and magnesium as an adjunctive approach to treatment of hypertension with antihypertensive medication. Am J Hypertens 1997; 10: 198A.
44. Omvik P, Myking OL. Unchanged central hemodynamics after six months of moderate sodium restriction with or without potassium supplement in essential hypertension. Blood Pressure 1995; 4: 32-41.
45. Münzel M, Drücke T. A comprehensive review of the salt and blood pressure relationship. Am J Hypertens 1992; 5: S1-42.
46. Katori M, Masataka M. Pivotal role of renal kallikrein-kinin system in the development of hypertension and approaches to new drugs based on this relationship. Jpn J Pharmacol 1996; 70: 95-128.
47. Ruskoaho H. Effects of drug treatment on hypertension and cardiac hypertrophy in spontaneously hypertensive rats. Acta Univ Oul D 96 Pharmacol Physiol 1983; 17: 69-71.
48. Kogi K, Satoh T. Contribution of isosorbide-5-mononitrate, a major metabolite of isosorbide dinitrate (ISDN), to the hemodynamic effect of ISDN administered orally in conscious dogs. Jpn J Pharmacol 1987; 44: 249-57.
49. Messerli FH, Schmieder R. Left ventricular hypertrophy. A cardiovascular risk factor in essential hypertension. Drugs 1986; 31 (Suppl 4): 192-201.
50. Fields NG, Yuan BX, Leenen FH. Sodium-induced cardiac hypertrophy. Cardiac sympathetic activity versus volume load. Circ Res 1991; 68: 745-55.
51. Hayakawa H, Raij L. The link among nitric oxide synthase activity, endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 1997; 29: 235-41.
52. Hayakawa H, Coffee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: effects of antihypertensive therapy. Circulation 1997; 96: 2407-13.
53. Tolins JP, Palmer RMJ, Moncada S, Raij L. Role of endothelium-derived relaxing factor in regulation of renal hemodynamic responses. Am J Physiol 1990; 258: H655-62.
54. Shortt C, Flynn A. Sodium-calcium interrelationships with specific reference to osteoporosis. Nutr Res Rev 1990; 3: 101-15.
55. MacGregor GA, Cappuccio FP. The kidney and essential hypertension: a link to osteoporosis. J Hypertens 1993; 11(8): 781-5.